09 Apr 2024 Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses Investors | Therapeutics
06 Mar 2024 Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Therapeutics
19 Jan 2024 Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development Investors | Therapeutics
13 Dec 2023 ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data Investors | Therapeutics